261 results
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
Disease Designation (“RPDD”) for SLS-005 in Sanfilippo Syndrome from the FDA. RPDD is an incentive program created under the Federal Food, Drug … during fiscal year 2023 (the “Named Executive Officers”):
Name and Position(s)
Year
Salary
Option
Awards(1)
Non-Equity
Incentive
Plan
Compensation
All
S-8
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
and Restated 2012 Stock Long Term Incentive Plan
(Full title of the plans)
Raj Mehra, Ph.D.
President, Chief Executive Officer and Chairman of the Board … Term Incentive Plan (the “2012 Plan”), which includes 106,188 shares of Common Stock issuable pursuant to options granted pursuant to the 2012 Plan
S-8
EX-5.1
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
the Company’s Amended and Restated 2012 Stock Long Term Incentive Plan (as amended to date, the “Plan”). This opinion letter is being delivered at your
S-8
SEEL
Seelos Therapeutics Inc
6 Mar 24
Registration of securities for employees
5:38pm
pursuant to the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan
Equity
Common Stock, par value $0.001 per share … , reserved for issuance pursuant to the Seelos Therapeutics, Inc. Amended and Restated 2012 Stock Long Term Incentive Plan
Total Offering Amounts
Total
424B5
97wsm
30 Jan 24
Prospectus supplement for primary offering
6:05am
DEFA14A
11oiyx 0i5
22 Dec 23
Additional proxy soliciting materials
4:01pm
424B5
sviv0oktjhl
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
da4nu4cecfujtm in
28 Nov 23
Prospectus supplement for primary offering
4:06pm
8-K
b9gt7rh
28 Nov 23
Material Modifications to Rights of Security Holders
9:00am
8-K
EX-99.1
x7zond
24 Nov 23
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
12:07pm
8-K
EX-99.1
0moh6lh5s160k 35jk
24 Nov 23
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
11:10am